Loading...

Home
ETF
CLRB

CLRB

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

CLRB News

Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane

Jan 12 2026Benzinga

Cellectar Plans to Submit iopofosine I 131 for European Approval in 3Q 2026

Jan 09 2026Globenewswire

Cellectar Plans to Submit iopofosine I 131 for Conditional Approval in Europe by 3Q 2026

Jan 09 2026Newsfilter

Cellectar Biosciences Secures Multi-Year Supply Agreement with Ionetix for Key Radioisotopes

Dec 16 2025Globenewswire

Cellectar Biosciences Signs Multi-Year Supply Agreement with Ionetix for Key Radioisotopes

Dec 16 2025Newsfilter

Cellectar Indicates 2027 Worldwide Release for Iopofosine as Regulatory Progress Gains Speed

Nov 13 2025SeekingAlpha

Cellectar Biosciences Announces Financial Results for Q3 2025 and Shares Corporate Developments

Nov 13 2025Newsfilter

Cellectar Biosciences, Inc. Secures $5.8 Million Through New Agreements

Oct 07 2025Newsfilter

Cellectar and Evestia Form Alliance to Advance Clinical Trial of Auger-Emitting Radiopharmaceutical for Triple-Negative Breast Cancer (TNBC)

Sep 24 2025Newsfilter

Cellectar Biosciences and ITM Sign Supply Agreement for GMP-Grade Actinium-225

Sep 11 2025Newsfilter

Innovative Cancer Treatments Drive Regulatory Progress Amid Global Market Growth

Sep 02 2025Newsfilter

Cellectar Biosciences to Share Findings in Oral Presentation and Panel Discussions at AACR Special Conference on Pediatric Cancer Discovery and Innovation

Aug 27 2025Newsfilter

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 14 2025Newsfilter

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

Aug 07 2025Newsfilter

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

Jul 02 2025Newsfilter

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

Jul 01 2025Newsfilter